Page 7 - Patrick Wingrove News Today

(Reuters) -Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's rival obesity drug Wegovy to hit around $7.5 billion. Pfizer last week said it would not advance its highly-anticipated oral obesity drug danugl...

(Reuters) - Johnson & Johnson on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzale...

Some leading US obesity specialists say they expect Eli Lilly’s powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s popular Wegovy.

Some leading U.S. obesity specialists say they expect Eli Lilly’s powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s popular Wegovy as they belong...

Novo Nordisk on Thursday said it sued one compounding pharmacy and refiled a lawsuit against another after finding their products claiming to contain the active ingredient for its in-demand weight-loss drug were impure.

By Patrick Wingrove (Reuters) -Novo Nordisk said on Thursday it sued one compounding pharmacy and refiled a lawsuit against another after finding their ...

Eleven people suffered bouts of dangerously low blood sugar in Lebanon this year, one of whom required hospitalization, after injecting suspected fake versions of Novo Nordisk's diabetes drug Ozempic, according Lebanese health officials. A director for the Lebanese Ministry of Public Health, Rita Karam, said officials suspected the drugs were fake after discovering the doses were different from the ones calibrated for authentic Ozempic injector pens. Explosive demand for Ozempic and other...

Eleven people suffered bouts of dangerously low blood sugar in Lebanon this year, one of whom required hospitalization, after injecting suspected fake versions of Novo Nordisks diabetes drug...

(Reuters) -Eleven people suffered bouts of dangerously low blood sugar in Lebanon this year, one of whom required hospitalization, after injecting suspected fake versions of Novo Nordisk's diabetes drug Ozempic, according Lebanese health officials. A director for the Lebanese Ministry of Public Health, Rita Karam, said officials suspected the drugs were fake after discovering the doses were different from the ones calibrated for authentic Ozempic injector pens. Explosive demand for Ozempic ...

Novo Nordisk on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday. Early data from the Danish drugmaker's Select trial released in August demonstrated that Wegovy, which has been shown to help patients lose an average of 15% of their weight, also reduced incidence of heart attack, stroke or death from heart disease by 20%. Full results fro...